S. J. Livingstone, D. Levin, H. C. Looker, R. S. Lindsay, S. H. Wild et al., Estimated Life Expectancy in a Scottish Cohort With Type 1 Diabetes, JAMA, vol.313, issue.1, p.37, 2008.

C. E. Mogensen and C. K. Christensen, Predicting Diabetic Nephropathy in Insulin-Dependent Patients, N Engl J Med, vol.311, issue.2, pp.89-93, 1984.

T. J. Orchard, A. M. Secrest, R. G. Miller, and T. Costacou, In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study, Diabetologia, vol.53, issue.11, pp.2312-2321, 2010.

T. Deckert, B. Feldt-rasmussen, K. Borch-johnsen, T. Jensen, and A. Kofoed-enevoldsen, Albuminuria reflects widespread vascular damage. The Steno hypothesis, Diabetologia, vol.32, issue.4, pp.219-245, 1989.

P. Groop, M. C. Thomas, J. L. Moran, J. Waden, L. M. Thorn et al., The Presence and Severity of Chronic Kidney Disease Predicts All-Cause Mortality in Type 1 Diabetes, Diabetes, vol.58, issue.7, pp.1651-1659, 2009.

R. J. Macisaac, C. Tsalamandris, S. Panagiotopoulos, T. J. Smith, K. J. Mcneil et al., Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care, vol.27, pp.195-200, 2004.

G. Penno, E. Russo, M. Garofolo, D. G. Lucchesi, D. Giusti et al., Evidence for two distinct phenotypes of chronic kidney disease in individuals with type 1 diabetes mellitus, Diabetologia, vol.60, issue.6, pp.1102-1115, 2017.

M. L. Caramori, P. Fioretto, and M. Mauer, Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: An indicator of more advanced glomerular lesions, Diabetes, vol.52, issue.4, pp.1036-1076, 2003.

A. S. Krolewski, J. Skupien, P. Rossing, and J. H. Warram, Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes, Kidney Int, vol.91, issue.6, pp.1300-1311, 2017.

V. Rigalleau, L. Blanco, L. Alexandre, E. Pupier, C. Lasseur et al., Normoalbuminuric chronic kidney disease in type 1 diabetes: is it real and is it serious? Diabetologia, pp.2121-2123, 2017.

I. Bebu, B. H. Braffett, T. J. Orchard, G. M. Lorenzi, J. M. Lachin et al., Mediation of the Effect of Glycemia on the Risk of CVD Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. Diabetes Care, 2019.

J. A. Hirst, K. S. Taylor, R. J. Stevens, C. L. Blacklock, N. W. Roberts et al., The impact of renin-angiotensin-aldosterone system inhibitors on Type 1 and Type 2 diabetic patients with and without early diabetic nephropathy, Kidney Int, vol.81, issue.7, pp.674-83, 2012.

, de la protéinurie et les traitements agissant au niveau glomérulaire comme les inhibiteurs de l'enzyme de conversion de l'angiotensine ou les antagonistes du récepteur de l'angiotensine II. Ainsi, il convient d

L. De and . Qu, il s'agit d'une étude longitudinale sur huit ans, avec un suivi qui n'avait pas été rapporté jusqu'à maintenant. Les limites sont le faible effectif de la population, la mesure indirecte de la fonction rénale de nos patients et l'absence de donnée concernant l'hypertension artérielle, points discutés dans l'article, Bibliographie 1. International Diabetes Foundation. IDF Diabetes Atlas -8th Edition 2017. IDF Diabetes Atlas, 2017.

. Santé and . Omdl, Rapport mondial sur le diabète, 2016.

S. J. Livingstone, D. Levin, H. C. Looker, R. S. Lindsay, S. H. Wild et al., Estimated Life Expectancy in a Scottish Cohort With Type 1 Diabetes, JAMA, vol.313, issue.1, p.37, 2008.

C. E. Mogensen and C. K. Christensen, Predicting Diabetic Nephropathy in Insulin-Dependent Patients, N Engl J Med, vol.311, issue.2, pp.89-93, 1984.

T. J. Orchard, A. M. Secrest, R. G. Miller, and T. Costacou, In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study, Diabetologia, vol.53, issue.11, pp.2312-2321, 2010.

R. C. Atkins, The epidemiology of chronic kidney disease, Kidney Int Suppl, issue.94, p.14, 2005.

M. Narres, H. Claessen, S. Droste, T. Kvitkina, M. Koch et al., The Incidence of End-Stage Renal Disease in the Diabetic (Compared to the Non-Diabetic) Population: A Systematic Review, PLoS One, vol.11, issue.1, p.147329, 2016.

D. Control, C. Group, D. M. Nathan, S. Genuth, J. Lachin et al., The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, N Engl J Med, vol.329, issue.14, pp.977-86, 1993.

S. Teppala, A. Shankar, and C. Sabanayagam, Association between IGF-1 and chronic kidney disease among US adults, Clin Exp Nephrol, vol.14, issue.5, pp.440-444, 2010.

M. D. Breyer, E. Bö, F. C. Brosius, T. M. Coffman, R. C. Harris et al., Mouse Models of Diabetic Nephropathy, J Am Soc Nephrol, vol.16, pp.27-45, 2005.

R. Z. Alicic, M. T. Rooney, and K. R. Tuttle, Diabetic kidney disease: Challenges, progress, and possibilities, Clin J Am Soc Nephrol, vol.12, issue.12, pp.2032-2077, 2017.

P. Fioretto and M. Mauer, Histopathology of Diabetic Nephropathy, Semin Nephrol, vol.27, issue.2, pp.195-207, 2007.

N. L. Baker, K. J. Hunt, D. R. Stevens, G. Jarai, G. D. Rosen et al., Association Between Inflammatory Markers and Progression to Kidney Dysfunction: Examining Different Assessment Windows in Patients With Type 1 Diabetes. Diabetes Care, 2017.

M. Giordano, T. Ciarambino, P. Castellino, A. Cataliotti, L. Malatino et al., Long-term effects of moderate protein diet on renal function and low-grade inflammation in older adults with type 2 diabetes and chronic kidney disease, Nutrition, vol.30, issue.9, pp.1045-1054, 2014.

J. Wada and H. Makino, Inflammation and the pathogenesis of diabetic nephropathy, Clin Sci, vol.124, issue.3, pp.139-52, 2013.

C. E. Mogensen and . Microalbuminuria, blood pressure and diabetic renal disease: Origin and development of ideas, Diabetologia, pp.263-85, 1999.

A. S. Krolewski, J. Skupien, P. Rossing, and J. H. Warram, Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes, Kidney Int, vol.91, issue.6, pp.1300-1311, 2017.

M. Monlun, L. Blanco, L. Alexandre, K. Mohammedi, and V. Rigalleau, Predictors of early renal function decline in Type 1 diabetes: retinopathy, Diabet Med, vol.35, issue.2, 2018.

R. J. Macisaac, C. Tsalamandris, S. Panagiotopoulos, T. J. Smith, K. J. Mcneil et al., Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care, vol.27, pp.195-200, 2004.

R. Retnakaran, C. A. Cull, K. I. Thorne, A. I. Adler, R. R. Holman et al., Risk Factors for Renal Dysfunction in Type 2 Diabetes: U.K. Prospective Diabetes Study 74, Diabetes, vol.55, issue.6, pp.1832-1841, 2006.

C. Chen, C. Wang, C. Hu, Y. Han, L. Zhao et al., Normoalbuminuric diabetic kidney disease. Front Med, vol.11, pp.310-318, 2017.

G. Penno, E. Russo, M. Garofolo, D. G. Lucchesi, D. Giusti et al., Evidence for two distinct phenotypes of chronic kidney disease in individuals with type 1 diabetes mellitus, Diabetologia, vol.60, issue.6, pp.1102-1115, 2017.

M. L. Caramori, P. Fioretto, and M. Mauer, Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: An indicator of more advanced glomerular lesions, Diabetes, vol.52, issue.4, pp.1036-1076, 2003.

V. Rigalleau, L. Blanco, L. Alexandre, E. Pupier, C. Lasseur et al., Normoalbuminuric chronic kidney disease in type 1 diabetes: is it real and is it serious?, pp.2121-2123, 2017.

V. Rigalleau, C. Lasseur, C. Raffaitin, M. Beauvieux, N. Barthe et al., Normoalbuminuric Renal-Insufficient Diabetic Patients: A lower-risk group. Diabetes Care, vol.30, pp.2034-2043, 2007.

P. Groop, M. C. Thomas, J. L. Moran, J. Waden, L. M. Thorn et al., The Presence and Severity of Chronic Kidney Disease Predicts All-Cause Mortality in Type 1 Diabetes, Diabetes, vol.58, issue.7, pp.1651-1659, 2009.

T. Deckert, B. Feldt-rasmussen, K. Borch-johnsen, T. Jensen, and A. Kofoed-enevoldsen, Albuminuria reflects widespread vascular damage. The Steno hypothesis, Diabetologia, vol.32, issue.4, pp.219-245, 1989.

M. E. Cooper, F. Bonnet, M. Oldfield, and K. Jandeleit-dahm, Mechanisms of diabetic vasculopathy: An overview, American Journal of Hypertension, pp.475-86, 2001.

R. T. Hurst and R. W. Lee, Increased incidence of coronary atherosclerosis in type 2 diabetes mellitus: mechanisms and management. Annals of internal medicine, pp.824-858, 2003.

Z. T. Bloomgarden, Consequences of Diabetes: Cardiovascular disease. Diabetes Care, pp.1825-1856, 2004.

S. Rahman, T. Rahman, A. Ismail, and A. Rashid, Diabetes-associated macrovasculopathy: Pathophysiology and pathogenesis. Diabetes, Obesity and Metabolism, pp.767-80, 2007.

A. E. Duncan, Hyperglycemia and perioperative glucose management, Curr Pharm Des, vol.18, issue.38, pp.6195-203, 2012.

S. P. Laing, A. J. Swerdlow, S. D. Slater, A. C. Burden, A. Morris et al., Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes, Diabetologia, vol.46, issue.6, pp.760-765, 2003.

S. P. Gray and K. Jandeleit-dahm, The pathobiology of diabetic vascular complicationscardiovascular and kidney disease, Journal of Molecular Medicine, pp.441-52, 2014.

A. Ceriello, S. Kumar, L. Piconi, K. Esposito, and D. Giugliano, Simultaneous control of hyperglycemia and oxidative stress normalizes endothelial function in type 1 diabetes, Diabetes Care, vol.30, issue.3, pp.649-54, 2007.

S. Pilemann-lyberg, T. W. Hansen, N. Tofte, S. A. Winther, S. Theilade et al., Uric Acid is an Independent Risk Factor for Decline in Kidney Function, Cardiovascular Event and Mortality in Patients With Type 1 Diabetes, Diabetes Care, 2019.

D. M. Nathan, I. Bebu, B. H. Braffett, J. M. Lachin, T. J. Orchard et al., Risk factors for cardiovascular disease in type 1 diabetes, Diabetes, vol.65, issue.5, pp.1370-1379, 2016.

S. D. De-ferranti, D. Boer, I. H. Fonseca, V. Fox, C. S. Golden et al., Type 1 diabetes mellitus and cardiovascular disease: A scientific statement from the American Heart Association and American Diabetes Association. Diabetes Care, pp.2843-63, 2014.

R. R. Huxley, S. Peters, G. D. Mishra, and M. Woodward, Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: A systematic review and meta-analysis, Lancet Diabetes Endocrinol, vol.3, issue.3, pp.198-206, 2015.

K. Matsushita, J. Coresh, Y. Sang, J. Chalmers, C. Fox et al., Kidney measures beyond traditional risk factors for cardiovascular prediction: A collaborative metaanalysis HHS Public Access, Lancet Diabetes Endocrinol, vol.3, issue.7, pp.514-539, 2015.

I. Bebu, B. H. Braffett, T. J. Orchard, G. M. Lorenzi, J. M. Lachin et al., Mediation of the Effect of Glycemia on the Risk of CVD Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. Diabetes Care, 2019.

Y. M. Nakao, S. Teramukai, S. Tanaka, S. Yasuno, A. Fujimoto et al., Effects of renin-angiotensin system blockades on cardiovascular outcomes in patients with diabetes mellitus: A systematic review and meta-analysis, Diabetes Res Clin Pract, vol.96, issue.1, pp.68-75, 2012.

E. J. Lewis, L. G. Hunsicker, R. P. Bain, and R. D. Rohde, The effect of angiotensin-convertingenzyme inhibition on diabetic nephropathy. The Collaborative Study Group, N Engl J Med, vol.329, issue.20, pp.1456-62, 1993.

J. A. Hirst, K. S. Taylor, R. J. Stevens, C. L. Blacklock, N. W. Roberts et al., The impact of renin-angiotensin-aldosterone system inhibitors on Type 1 and Type 2 diabetic patients with and without early diabetic nephropathy, Kidney Int, vol.81, issue.7, pp.674-83, 2012.

J. Cheng, W. Zhang, X. Zhang, F. Han, X. Li et al., Effect of angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: A meta-analysis, JAMA Intern Med, vol.174, issue.5, pp.773-85, 2014.

L. Laffel, J. B. Mcgill, S. Louis, and D. J. Gans, The Beneficial Effect of Angiotensin-Converting Enzyme Inhibition With Captopril on Diabetic Nephropathy in Normotensive IDDM Patients With Microalbuminuria

R. Bilous, N. Chaturvedi, A. K. Sjølie, J. Fuller, R. Klein et al., Effect of Candesartan on Microalbuminuria and Albumin Excretion Rate in Diabetes, Ann Intern Med. American College of Physicians, vol.151, issue.1, p.11, 2009.

M. Mauer, B. Zinman, R. Gardiner, S. Suissa, A. Sinaiko et al., Renal and Retinal Effects of Enalapril and Losartan in Type 1 Diabetes, N Engl J Med, vol.361, issue.1, pp.40-51, 2009.

E. R. Mathiesen, E. Hommel, H. P. Hansen, U. M. Smidt, and H. Parving, Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria, BMJ, vol.319, issue.7201, pp.24-29, 2011.

D. N. Koye, D. J. Magliano, C. M. Reid, C. Jepson, H. I. Feldman et al., Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study, Am J Kidney Dis, vol.72, issue.5, pp.653-61, 2018.

G. Comai, D. Malvi, A. Angeletti, F. Vasuri, S. Valente et al., Histological Evidence of Diabetic Kidney Disease Precede Clinical Diagnosis, Am J Nephrol, pp.1-8, 2019.

G. Dogra, L. Rich, K. Stanton, and G. F. Watts, Endothelium-dependent and independent vasodilation studies at normoglycaemia in type I diabetes mellitus with and without microalbuminuria, Diabetologia, vol.44, issue.5, pp.593-601, 2001.

C. N. Rathcke, F. Persson, L. Tarnow, P. Rossing, and H. Vestergaard, YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria. Diabetes Care, vol.32, pp.323-331, 2009.

C. N. Rathcke and H. Vestergaard, YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflammation Research, pp.221-228, 2006.

C. Dessapt, J. Karalliedde, M. Hernandez-fuentes, P. Martin, P. Maltese et al., Circulating vascular progenitor cells in patients with type 1 diabetes and microalbuminuria. Diabetes Care, vol.33, pp.875-882, 2010.

G. Maltese, N. Fountoulakis, R. C. Siow, L. Gnudi, and J. Karalliedde, Perturbations of the antiageing hormone Klotho in patients with type 1 diabetes and microalbuminuria, vol.60, pp.911-915, 2017.

J. L. Gross, D. Azevedo, M. J. Silveiro, S. P. Canani, L. H. Caramori et al., Diabetic nephropathy: Diagnosis, prevention, and treatment. Diabetes Care, pp.164-76, 2005.

F. Wotherspoon, D. W. Laight, D. L. Browne, C. Turner, D. R. Meeking et al., Plasma homocysteine, oxidative stress and endothelial function in patients with Type 1 diabetes mellitus and microalbuminuria, Diabet Med, vol.23, issue.12, pp.1350-1356, 2006.

, Serment d'Hippocrate

, Au moment d'être admise à exercer la Médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences

, Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire

, Admise dans l'intimité des personnes, je tairai les secrets qui me seront confiés. Reçue à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs

, Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément

, Je préserverai l'indépendance nécessaire à l'accomplissement de ma mission

, Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses